2]. The underlying mechanism for this protective effect
has not yet been elucidated; however, considering the role of HLA molecules in the presentation of viral antigens to T cells, a role for cytotoxic T lymphocytes (CTLs) seems to be likely.
Several lines of evidence point to a central role of CTLs in the control of viral replication during asymptomatic HIV-1 infection [3] [4] [5] [6] [7] . CTL pressure, however, may select for escape variants of HIV-1 that are capable of evading antigen presentation to T cells or CTL recognition. Escape of HIV-1 from CTLs has been observed in humans [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] as well as in animal models [17] [18] [19] [20] [21] and is generally associated with increased viral replication and progressive loss of CD4 ϩ T cells.
Several studies have implied that at least certain CTL escape mutations can come at a fitness cost to the virus [22] [23] [24] . One of the most prominent examples of loss of viral fitness has been associated with the T242N mutation in the HLA-B57-restricted TW10 epitope in Gag, and this loss of fitness has been used as one of the explanations for the association between HLA-B57 and a long-term nonprogressive clinical course of HIV infection [22] .
Despite the clear association between HLA-B57/5801 and long-term nonprogressive HIV infection, a substantial group of HIV-infected individuals expressing the HLA-B57/5801 allele has demonstrated relatively rapid progression to AIDS [25] . In a study from our group published elsewhere [26] , the T242N mutation in the HLA-B57/5801-restricted TW10 Gag epitope in HIV-1 was present in all viruses from both individuals with disease progression (known as "progressors") and LTNPs expressing HLA-B57/5801 from the Amsterdam Cohort Studies on HIV Infection and AIDS (hereafter referred to as the "Amsterdam Cohort Studies"). In addition, the frequencies of CTLs directed against wild-type sequences and autologous CTL escape variants of the 4 known HLA-B57/5801 epitopes in Gag were similar in progressors and LTNPs. Thus, this finding could not explain the observed differences in the clinical course of disease.
In the present study, we focused on Nef-specific CTLs and sequence dynamics in 4 previously described CTL epitopes in Nef, to test whether they are associated with the differential clinical course of infection in our group of LTNPs and progressors expressing HLA-B57/5801.
METHODS

Study subjects. All participants from the Amsterdam Cohort
Studies who carried the HLA-B57 or HLA-B5801 allele (n ϭ 22) were selected for inclusion in the present study (table 1) . Fourteen individuals were HIV-1 infected (had HIV-1 seroprevalence) at the moment of entry in the cohort studies, and 8 individuals demonstrated seroconversion for HIV antibodies during active follow-up. All cohort participants made routine visits to donate blood and undergo physical examination every 3 months. After being selected for this study on the basis of HLA-B57/5801 expression, participants had their HLA-B type confirmed using high-resolution HLA typing [27] . Individuals who Five progressors (P9 -P13) and 5 LTNPs (L5-L9) were analyzed longitudinally. Three participants (L6, L7, and L1) were heterozygous for the 32-bp deletion within CCR5, whereas all other participants had a CCR5 wild-type genotype. All study participants were therapy naive during the study period.
Typing of the HLA-A and -B alleles of all participants did not reveal other HLA types that were associated with a difference in disease progression, with the exception of P3, whose HLA-B type was HLA-B*3502. This allele is known to accelerate the clinical course of infection.
Isolation of biological virus clones and sequence analysis. Clonal HIV-1 variants were obtained as described elsewhere [28] . In short, DNA was isolated from HIV-negative donor peripheral blood mononuclear cells (PBMCs) infected with clonal HIV-1 variants, by use of the L6 method [29] . Nef DNA was amplified using a nested polymerase chain reaction (PCR) with the following outer primers-Nef-1 forward (fw) primer AGCCATAGCAGTAGCTGAGG and Nef-1 reverse (rev) primer GCTTATATGCAGGATCTGAGG-and the following inner primers-Nef-2 fw primer AGCTTGTAGAGC-TATTCGCCACA and Nef-2 rev primer AGCAAGCTCGATGT-CAGCAG. PCR products were purified and sequenced using the ABI prism BigDye Terminator sequencing kit (Perkin Elmer) on an ABI 3130 XL DNA sequencer, according to the manufacturer's protocol.
Interferon (IFN)-␥ enzyme-linked immunospot (ELISPOT) assay. IFN-␥-producing antigen-specific CD8 ϩ T cells were measured using the IFN-␥ ELISPOT assay with the use of multiscreen, 96-well, membrane-bottomed plates (MSIPN4550; Millipore) and IFN-␥-specific monoclonal antibodies (Mabtech). Cryopreserved PBMCs were thawed and suspended in RPMI 1640 medium containing 10% fetal calf serum (FCS) and were incubated at a final concentration of 10 5 cells/well in triplicate.
Responses were measured against an excess concentration of 20 g/mL of the following peptides: HTQGYFPDWQ, NTQGYF-PDWQ, KGALDLSHF, KAALDLSHF, KAAVDLSHF, GPGIRY-PLTFGWCF, GPGVRYPLTFGWCY, and YFDPWQNYT. Responses against the HTQGYFPDWQ and NTQGYFPDWQ peptides were tested at additional concentrations of 0.1, 1, and 10 g/mL, to investigate potential differences in the ability to respond to low peptide concentrations. All peptides were synthesized by the peptide facility at The Netherlands Cancer Institute. Phytohemagglutinin (PHA) stimulation served as a positive control to test the capacity of PBMCs to produce IFN-␥, and medium without peptide or PHA served as a negative control. IFN-␥-producing cells were detected as dark spots and were counted using an A.EL.VIS EliScan (EliAnalyse software; version 4). The number of IFN-␥-producing cells was calculated by subtracting the negative control value and was reported as the number of spot-forming units per 10 6 PBMCs. Samples with Ͼ100 spot-forming units/million PBMCs, after subtraction of the negative control values, were considered to have positive results.
Analysis of the expression of inhibitory receptor "programmed death 1" (PD-1). PBMCs were resuspended in RPMI 1640 medium containing 10% FCS. Cells were incubated with ␣CD8-peridinin chlorophyll protein (PerCP) and ␣-programmed death fluorescein isothiocyanate (␣PD-1-FITC) for 20 min at 4°C (Becton Dickinson). Cells were fixed in cellfix (Becton Dickinson), and flow cytometry was performed. At least 300,000 events were acquired using the LSRII flow cytometer (Becton Dickinson). Lymphocytes were gated by forward and sideward scatter. PD-1 expression on total CD8
ϩ T cells was analyzed using Diva software (Becton Dickinson).
RESULTS
Sequence dynamics in 4 HLA-B57/5801-restricted CTL epitopes in Nef of HIV-1 variants isolated from LTNPs and progressors.
We performed a longitudinal analysis of the dynamics of CTL escape mutations in 4 well-defined HLA-B57/ 5801-restricted epitopes in Nef of clonal HIV-1 variants isolated from 5 HLA-B57/5801 progressors (table 2) and 5 HLA-B57/ 5801 LTNPs (table 3) . CTL escape mutations from 12 additional HLA-B57/5801 participants (8 progressors and 4 LTNPs) were analyzed at a single time point during infection. In the HLA-B57/5801-restricted Nef epitope YT9 (YFPD-WQNYT; amino acid positions 120 -128), sequence variation was found only in viruses from L8 that were isolated 137 months after seroconversion. Various potential CTL escape mutations occurred in HLA-B57/5801-restricted Nef epitopes KF9 (KGALDLSHF; amino acid positions 82-90) and GF14 (GP-GIRYPLTFGWCF; amino acid positions 130 -143) of HIV-1 variants isolated from both LTNPs and progressors. These are, therefore, not likely to influence the clinical course of infection. HIV-1 variants isolated from 12 progressors and 7 LTNPs harbored a H116N substitution in HLA-B57/5801-restricted Nef epitope HW9 (HTQGYFPDW; amino acid positions 116 -124), whereas viruses isolated from 3 individuals (L6, L9 and P4) lacked this mutation. Of the 5 progressors and 5 LTNPs from whom HIV-1 variants were isolated longitudinally, the substitution never appeared in 2 individuals (L6 and L9); however, it appeared during the course of infection in 2 individuals (L5 and P11), and it was already present in virus variants obtained at the earliest time points in the remaining 6 participants. The early selection of the H116N substitution indicates that this mutation might have a positive effect in an individual with HLA-B57/5801 
NOTE.
Consensus sequences of 4 known HLA-B57/5801-restricted epitopes in Nef (KF9, HW9, YT9, and GF14) and aligned predicted amino acid sequences of HIV variants from 13 progressors (denoted by "P" in column 1). Only sequence differences are shown. SC, seroconversion.
a Individuals who demonstrated seroconversion for HIV-1 antibodies during active follow-up in the cohort studies. b Lower limit of detection of the assay.
expression. Of interest, peptide prediction programs based on major histocompatibility complex binding, proteasomal cleavage, and transport of a transporter associated with antigen processing (epitope prediction and analysis tools are presented on the IEDB Analysis Resource Web site; available at: http:// tools.immuneepitope.org) did not reveal a difference in the processing and/or presentation of the H116N mutant epitope, compared with the wild-type sequence. HW9-specific CD8 ؉ T cell responses in LTNPs and progressors. To study whether both wild-type and virus variant epitopes were recognized, we measured CD8 ϩ T cell IFN-␥ responses against these 4 HLA-B57/5801-restricted Nef epitopes by use of the IFN-␥ ELISpot assay for 10 individuals (P9-P13 and L5-L9) at a relatively late time point during HIV infection (between 20 and 88 months after seroconversion or at study entry for progressors and between 40 and 170 months after seroconversion or at study entry for LTNPs). With the exception of LTNP L6, none of the individuals showed a CD8 ϩ T cell response against either the wild type or the autologous mutants of the KF9 and GF14 epitopes. 
Table 3. Sequence analysis of HLA-B57/5801-restricted cytotoxic T lymphocyte epitopes in Nef in HIV-1 isolates recovered from individuals with a long-term nonprogressive clinical course of disease (LTNPs).
Analysis, patient
NOTE.
Consensus sequences of 4 known HLA-B57/5801-restricted epitopes in Nef (KF9, HW9, YT9, and GF14) and aligned predicted amino acid sequences of HIV variants from 9 LTNPs (denoted by an "L" in column 1). Only sequence differences are shown. SC, seroconversion.
a Lower limit of detection of the assay. b Individuals who demonstrated seroconversion for HIV-1 antibodies during active follow-up in the cohort studies.
CD8
ϩ T cell IFN-␥ responses against the YT9 (YFPDWQ-NYT) peptide were observed in 3 progressors (P10 -P12) and in 1 LTNP (L6) (data not shown). At the same time points, 3 of 5 LTNPs showed CD8 ϩ IFN-␥ T cell responses against the wild-type HW9 epitope, even at low peptide concentrations, whereas none of the progressors showed a significant response to the wild-type HW9 epitope ( figure 1A) . CD8 ϩ T cell reactivity against the H116N mutant epitope was tested only for those patients who actually had developed the mutant HIV-1 variant, with L6 and L9 excluded from the analysis. After stimulation with the H116N mutant epitope, IFN-␥ production was observed for CD8 ϩ T cells from only 1 individual (L5), and it was noted only when the highest peptide concentration was used (figure 1B).
To study whether the absence of CTL responses against the wild-type HW9 epitope and the H116N mutant could be due to exhaustion at this relatively late time point during infection, we analyzed T cell responses at an earlier time point (between 6 and 35 months after seroconversion or at the time of study entry for progressors and between 11 and 42 months after seroconversion or at the time of study entry for LTNPs). As depicted in figure 1A , 4 of 5 LTNPs and 2 of 5 progressors showed a clear response to the HW9 epitope at the earlier time point. T cells from LTNPs in whom HIV-1 variants with the H116N escape mutation were present also showed T cell reactivity against the mutant peptide, whereas no responses were observed after stimulation of progressor CD8 ϩ T cells with the H116N mutant epitope ( figure  1B) . These results show that, although functional HW9-specific CD8 ϩ T cell responses were present early during infection in at least some progressors, they were apparently lost late during infection.
Up-regulation of PD-1 expression during chronic HIV-1 infection. Several studies have recently shown that expression of PD-1 is up-regulated on the surface of exhausted T cells in mice [30] , and PD-1 up-regulation has been implicated as a mechanism for failing CD8 ϩ T cell responses in individuals with progressive HIV infection [31, 32] . To investigate the expression of this marker on the total CD8 ϩ T cell population in our group of HLA-B57/5801-positive progressors and LTNPs, we measured, early and late during infection, PD-1 expression on gated CD8 ϩ T cells from 9 individuals who were studied longitudinally. A representative dot-plot analysis of PD-1 staining in an LTNP (L6) and a progressor (P11) is shown in figure 2A . P9 was excluded from this analysis because of a paucity of PBMCs at the figure 2B , PD-1 expression was up-regulated at a late time point in both progressors and LTNPs (figure 2B) (for the comparison of early vs. late time points during infection in the whole study population, P ϭ .02, by Wilcoxon signed rank test). Up-regulation of PD-1 during chronic HIV-1 infection was somewhat more pronounced in progressors (P ϭ .068, by Wilcoxon signed rank test) than in LTNPs (P ϭ .225, by Wilcoxon signed rank test). Furthermore, already early after infection, PD-1 expression tended to be higher in progressors than in LTNPs, albeit not significantly higher.
DISCUSSION
It has been hypothesized that the less progressive clinical course of HIV-1 infection in individuals expressing HLA-B57/B5801 may be explained by targeting HLA-B57/5801-restricted CTLs to epitopes in highly constrained regions of the virus [23, 24, 33] . Escape mutations in these epitopes would support evasion of HIV-1 from the immune system but would come at such a high fitness loss to the virus that the net effect would still be a reduced viral burden. The reversal of the T242N substitution in the HLA-B57-restricted TW10 epitope at the time of transmission from an HLA-B57-positive to an HLA-B57-negative individual [33] supports this idea.
Despite the association between HLA-B57/5801 and slow progression of HIV disease, HLA-B57/5801 is also present among HIV-1-infected patients with progressive disease. A previous study showed that all progressors expressing HLA-B57-but only some LTNPs expressing HLA-B57-had the T242N mutation in the TW10 epitope in Gag [25] . Frequencies of CTLs against the wild type and the escape variants were comparable in progressors and LTNPs with both wild-type and mutant viruses. This finding suggests that the CTL escape mediated by the T242N mutation has a more dramatic negative effect on the clinical course of infection than does the viral attenuation associated with it [25] . We found that the T242N substitution in the HLA-B57/5801-restricted TW10 Gag epitope was present both in progressors and in LTNPs, and that there was no difference in CD8 ϩ IFN-␥ responses against Gag consensus peptides or their autologous escape variants [26] .
In the present study, we focused on the Nef gene, because several reports have demonstrated a great influence of Nef on the course of disease. Even small deletions in Nef have been shown to have tremendous beneficial effects on the clinical course of infection, both in macaques [34, 35] and in humans [36 -38] . Moreover, CTLs directed against viral gene products that are expressed early in the viral life cycle may be more effective, because these would optimally curtail production of new virions from a newly infected cell [39, 40] .
Only in HIV-1 variants from LTNP L9 did we observe a single amino acid deletion in Nef (data not shown), which may help to explain the low viral load in this patient. Sequence diversity in the 4 HLA-B57/5801-restricted epitopes KF9, GF14, YT9, and HW9 was similar for HIV-1 variants from progressors and LTNPs. The H116N mutation in Nef, which has been described as an HLA-B57 escape variant [41, 42] and which is present in 25.3% of all Nef sequences in the Los Alamos database, was present in HIV-1 variants from all but 2 HLA-B57/5801 LTNPs and 1 progressor. This mutation, on its own, thus did not seem to be associated with the clinical course of infection.
Although HW9-specific CD8 ϩ T cell responses were present early during infection in at least some of the progressors and LTNPs; later during infection, T cells from progressors had lost the ability to produce IFN-␥ after in vitro stimulation with the HW9 peptide, whereas these responses were preserved in 3 of 5 LTNPs. Because the exact moment of seroconversion is not known for some of the patients, the early time point used for analysis in our study already may, in fact, be occurring relatively late during the course of infection. Thus, the absence of a response against HW9 at the earliest time point in some of the progressors does not exclude the possibility that a response had been present even earlier during infection. The presence of HIV-1-specific CD8 ϩ T cell responses at the earliest time point in 2 progressors suggests that the absence of T cell reactivity later during infection is not due to a complete inability to respond to the HW9 peptide but, rather, to an inability to preserve this immune response.
It has previously been shown that HIV-specific CD8 ϩ T cell responses get exhausted in the face of a high viral burden [31, 32] . Indeed, in our study, LTNPs had better preserved CD8 ϩ T cell responses against wild-type and mutant Nef peptides than did progressors [43, 44] . Moreover, up-regulation of PD-1 during chronic infection tended to be more pronounced in progressors than in LTNPs, a finding indicative of exhaustion of their CD8 ϩ T cells. This finding is in agreement with observations in a larger group of progressors and LTNPs with a wider HLA background [45] , although we did not see a significant correlation between viral load and PD-1 expression, as reported elsewhere [32] . This lack of a signficant correlation may have been due to the low number of subjects in our study. It was recently reported that high-avidity T cells are deleted as HIV infection progresses [46] . In line with this finding, we observed that T cells from LTNPs were responsive to lower peptide concentrations than were T cells from progressors, which suggests that the specific CD8 ϩ T cells in LTNPs had a higher avidity for their antigen [47, 48] . The exact underlying mechanism for exhaustion of the immune system is not known, although continuous immune activation driving T cell turnover has been implicated as a factor in this process [49] .
In the present study, we used the ability to produce IFN-␥ after in vitro stimulation as a marker of functional HIV-specific CD8 ϩ T cells. Although it has been shown that IFN-␥ production is the last function to be lost during chronic viral infection [50] , it is thought that the presence of polyfunctional T cells is an immunological correlate of protection against progression [44] . Possible differences in the presence of polyfunctional T cells between LTNPs and progressors may further contribute to the observed difference in clinical course.
In conclusion, we have shown here that the differences between the clinical course of HLA-B57/5801-expressing progressors and LTNPs do not relate to differences in CTL escape mutations in Nef epitopes but, rather, to a difference in preservation of CTL activity against the HW9 epitope in Nef. Although we cannot rule out the possibility that the maintenance of CTL activity against HW9 is a consequence rather than a cause of slow progression of disease, it is tempting to conclude that the ability to maintain CTL activity against such epitopes as the HW9 Nef epitope is contributing to a more benign course of HIV-1 infection.
